Recent Updates in Bispecific Therapies for Patients With Relapsed/Refractory Multiple Myeloma : Episode 5
Navigating Post–CAR T Progression: Therapy Selection and Targeting
Panelists discuss how sequential B-cell maturation agent (BCMA)–targeting therapies can be effective despite potential resistance patterns, with experts evaluating factors like prior response duration, alternative targets like GPRC5D or FcRH5, and patient-specific characteristics when deciding treatment sequencing after CAR T progression.
Video content above is prompted by the following:
- Can BCMA-targeting bispecifics be used in patients who have received prior BCMA-targeting CAR T therapies?
- When would you consider switching to a therapy hitting a different target?
- Describe your approach to treatment sequencing if a patient had received CAR T-cell therapy before bispecifics and progresses.
- Which therapies might you consider and why?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
